Association between risk factors and overall survival from first progression
| Variable . | n . | HR (95% CI) by univariable analysis . | P (HR) . | HR (95% CI) by multivariable analysis . | P (HR) . |
|---|---|---|---|---|---|
| Age | 452 | 1.02 (1.01-1.04) | .003 | — | — |
| Stage | — | — | |||
| 1-3 | 62 | — | — | ||
| 4 | 378 | 1.95 (1.17-3.27) | .010 | ||
| Splenomegaly | — | — | |||
| Yes | 210 | 1.50 (1.07-2.11) | .018 | ||
| No | 157 | — | — | ||
| LN >5 cm | — | — | |||
| Yes | 72 | 0.98 (0.64-1.50) | .928 | ||
| No | 247 | — | — | ||
| BM involvement | — | — | |||
| Yes | 315 | 1.91 (1.15-3.17) | .012 | ||
| No | 59 | — | — | ||
| Ki67% | — | — | |||
| >30 | 94 | 1.24 (0.76-2.03) | .384 | ||
| ≤30 | 93 | — | — | ||
| CK | — | — | |||
| Yes | 30 | 2.21 (1.12-4.36) | .022 | ||
| No | 121 | — | — | ||
| Blastoid histology | — | — | |||
| Yes | 61 | 1.93 (1.28-2.90) | .002 | ||
| No | 245 | — | — | ||
| Intensive treatment | — | — | |||
| Yes | 232 | 1.25 (0.92-1.72) | .157 | ||
| No | 198 | — | — | ||
| B symptoms | |||||
| Yes | 126 | 1.41 (1.02-1.96) | .037 | 1.27 (0.75-2.15) | 0.376 |
| No | 276 | — | — | — | — |
| MIPI risk score | |||||
| High risk | 67 | 2.45 (1.38-4.32) | .002 | 2.14 (1.19-3.85) | 0.011 |
| Intermediate risk | 72 | 1.24 (0.67-2.30) | .485 | 1.24 (0.66-2.33) | 0.499 |
| Low risk | 74 | — | — | — | — |
| Time to POD | |||||
| PRF/POD6 | 65 | 3.76 (2.46-5.75) | <.001 | 2.71 (1.42-5.17) | 0.002 |
| POD6-24 | 153 | 2.12 (1.53-2.93) | <.001 | 1.33 (0.75-2.35) | 0.324 |
| POD>24 | 237 | — | — | — | — |
| Variable . | n . | HR (95% CI) by univariable analysis . | P (HR) . | HR (95% CI) by multivariable analysis . | P (HR) . |
|---|---|---|---|---|---|
| Age | 452 | 1.02 (1.01-1.04) | .003 | — | — |
| Stage | — | — | |||
| 1-3 | 62 | — | — | ||
| 4 | 378 | 1.95 (1.17-3.27) | .010 | ||
| Splenomegaly | — | — | |||
| Yes | 210 | 1.50 (1.07-2.11) | .018 | ||
| No | 157 | — | — | ||
| LN >5 cm | — | — | |||
| Yes | 72 | 0.98 (0.64-1.50) | .928 | ||
| No | 247 | — | — | ||
| BM involvement | — | — | |||
| Yes | 315 | 1.91 (1.15-3.17) | .012 | ||
| No | 59 | — | — | ||
| Ki67% | — | — | |||
| >30 | 94 | 1.24 (0.76-2.03) | .384 | ||
| ≤30 | 93 | — | — | ||
| CK | — | — | |||
| Yes | 30 | 2.21 (1.12-4.36) | .022 | ||
| No | 121 | — | — | ||
| Blastoid histology | — | — | |||
| Yes | 61 | 1.93 (1.28-2.90) | .002 | ||
| No | 245 | — | — | ||
| Intensive treatment | — | — | |||
| Yes | 232 | 1.25 (0.92-1.72) | .157 | ||
| No | 198 | — | — | ||
| B symptoms | |||||
| Yes | 126 | 1.41 (1.02-1.96) | .037 | 1.27 (0.75-2.15) | 0.376 |
| No | 276 | — | — | — | — |
| MIPI risk score | |||||
| High risk | 67 | 2.45 (1.38-4.32) | .002 | 2.14 (1.19-3.85) | 0.011 |
| Intermediate risk | 72 | 1.24 (0.67-2.30) | .485 | 1.24 (0.66-2.33) | 0.499 |
| Low risk | 74 | — | — | — | — |
| Time to POD | |||||
| PRF/POD6 | 65 | 3.76 (2.46-5.75) | <.001 | 2.71 (1.42-5.17) | 0.002 |
| POD6-24 | 153 | 2.12 (1.53-2.93) | <.001 | 1.33 (0.75-2.35) | 0.324 |
| POD>24 | 237 | — | — | — | — |
BM, bone marrow; LN, lymph node.